Abstract
The syndrome of congestive heart failure is characterized by a reduced stroke volume and peripheral circulatory changes that redistribute blood flow to metabolically active tissues. Conventional inotropic therapy has been limited by the moderate potency and marked toxicity of the glycosides [1] and the ob ligate i.v. route of administration of the catecholamines. Recent studies suggest that the potent effects of the catecholamines are also subject to tolerance after prolonged administration [2–5]. Thus, it is not surprising that considerable effort has been expended on developing new inotropic therapies that produce their effects by novel mechanisms of action and — in addition — exert considerable vasodilator properties at the same time. Whereas conventional therapeutic strategy attempts to improve ventricular performance by eliciting a “contractile reserve” from the failing heart, it now seems apparent it is the peripheral circulatory changes that predominantly govern functional capacity. An inotropic agent’s ability to reverse these peripheral circulatory changes is determined by its inotropic potency, vasodilating capacity, and sustained efficacy. The limitations of conventional therapies have therefore led to the development of new classes of nonglycosidic, nonadrenergic inotropic agents that seem to exert their effects by myocardial phosphodiesterase inhibition, by H2 receptor mediated adenylate cyclase stimulation and by calcium-sensitizing of myocardial contractile proteins. Although these potent ino tropes enhance exercise and aerobic capacity, they are palliative rather than curative agents.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Selzer A (1981) Digitalis in cardiac failure: do benefits justify risks? Arch Intern Med 141:18
Colucci WS, Alexander W, Williams GH et al. (1981) Decreased lymphocyte betaadrenergic receptor density in patients with heart failure and tolerance to the betaadrenergic agonist pirbuterol. N Engl J Med 305:185
Baumann G, Rieß G, Erhardt WD, Felix STB, Ludwig L, Blümel G, Blömer H (1981) Impaired beta-adrenergic stimulation in the uninvolved ventricle post-acute myocardial infarction: reversible defect due to decline in number and affinity of beta-receptors. Am Heart J 101:569
Baumann G, Mercader D, Busch U et al. (1983) Effects of H2-receptor agonist impromidine in human myocardium and patients with heart failure due to mitral and aortic valve disease. J Cardiovasc Pharmacol 5:618–625
Baumann G, Felix STB (1983) Zur pharmakologischen Stellung von Prenalterol. II. Versuch einer kritischen Wertung aus experimenteller und klinischer Sicht. Herz/Kreislauf 2:65
Zelis R, Lee G, Mason DT (1974) The influence of experimental edema on metabolically determined blood flow. Circ Res 34:482
Bristow MR, Ginsburg R, Minobe W et al. (1982) Decreased catecholamine sensi tivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 307:205
Zelis R, Delea CS, Coleman H et al. (1970) Arterial sodium content in experimental congestive heart failure. Circulation 41:213
Watkins L, Burkin LA, Haven E et al. (1976) The renin-angiotensin system in congestive heart failure in conscious dogs. J Clin Invest 57:1606
Mason DT, Zelis R, Longhurst J et al. (1977) Cardiocirculatory responses to muscular exercise in congestive heart failure. In: Sonnenblick EH, Lesch M (eds) Exercise and heart disease. Grune and Stratton, New York, p 229
LeJemtel TH, Maskin CS, Sinoway L et al. (1983) Fixed vasodilating capacity in exercising leg muscles: a limitation of aerobic capacity in heart failure. Clin Res 31:2 (abstr)
Zelis R, Longhurst J, Capone RJ et al. (1974) A comparison of regional blood flow and oxygen utilization during dynamic forearm exercise in normal subjects and patients with congestive heart failure. Circulation 50:137
Maskin CS, Forman R, Sonnenblick EH et al. (1983) Failure of dobutamine to increase exercise capacity. Am J Cardiol 51:177
Kugler J, Maskin C, Frishman WH et al. (1982) Regional and systemic metabolic effects of angiotensin converting enzyme inhibition during exercise in patients with severe heart failure. Circulation 66:1258
LeJemtel TH, Kugler J, Maskin CS et al. (1982) Captoril therapy in severe heart failure: delayed improvement in maximal oxygen uptake despite immediate hemodynamic effects. Acta Cardiol [Suppl] (Brux) 28:61
Lee AP, Ioe R, Blusey R et al. (1979) Long-term effects of physical training on coronary patients with impaired ventricular function. Circulation 60:1519
Siegel LA, Keung E, Siskind SJ et al. (1981) Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure. Circ Res 63:838
Siskind SJ, Sonnenblick EH, Forman R et al. (1981) Acute substantial benefits of inotropic therapy with amrinone on exercise hemodynamics and metabolism in se vere congestive heart failure. Circulation 64:966
Maskin CS, Sinoway L, Chadwick B et al. (1983) Sustained hemodynamic and clinical effects of a new cardiotonic agent WIN 47203 in patients with severe congestive heart failure. Circulation 67:1065
Wilson JR, Ferraro N (1983) Exercise intolerance in patients with chronic left heart failure: relation to oxygen transport and ventilatory abnormalities. Am J Cardiol 51:1358
Franciosa JA, Park M, Levine TB (1981) Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol 47:33
Dyke SH, Urschel CW, Sonnenblick EH et al. (1975) Detection of latent function in acutely ischemic myocardium in the dog. Circ Res 36:490
Braunwald E, Ross J, Frommer PL et al. (1964) Clinical observations on paired electrical stimulation of the heart. Am J Med 37:700
Sonnenblick EH, Frishman WH, LeJemtel TH (1979) Dobutamine: a new synthetic cardioactive sympathetic amine. N Engl J Med 300:17
Scholz H (1984) Inotropic drugs and their mechanism of action. J Am Coll Cardiol 4:389
Klein G, Wirtzfeld A, Schnelle K, Holzmüller W, Schinz A (1980) Hämodynamische und metabolische Wirkungen von Dobutamin und Prenalterol bei gesunden Probanden. In: Bleifeld W, Gattinge R, Schaper W, Brade W (eds) Internationales Dobutamin Symposium. Urban and Schwarzenberg, Munich
Williams RJ, Bishop Z (1981) Selectivity of dobutamine for adrenergic receptor subtypes: in vitro analysis by radioligand binding. J Clin Invest 67:1703
Unverferth DV, Blauford M, Kates RE et al. (1980) Tolerance to dobutamine after a 72-hour continuous infusion. Am J Med 69:262
Baumann G, Pfafferott C, Klein G (1988) Acute hemodynamic effects of dopexamine, dobutamine and sodium-nitroprusside in chronic heart failure. Eur Heart J 9:503
Baumann G, Felix STB, Rieß G, Loher U, Ludwig L, Blömer H (1984) Apparent superiority of H2-receptor stimulation and simultaneous ß-blockade over conventional treatment with /?-sympathomimetic drugs post-acute myocardial infarction. Agents Actions 15:216–228
Unverferth DV, Magorien RD, Altschuld R et al. (1983) The hemodynamic and metabolic advantages gained by a 3-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J 106:29
Leier CV, Huss P, Lewis RP et al. (1982) Drug-induced conditioning in congestive heart failure. Circulation 65:1382
Kenakin TP, Ferris RM (1983) Effects of in vivo beta-adrenoceptor down regulation on cardiac responses to prenalterol and pirbuterol. J Cardiovasc Pharmacol 5:90
Awan NA, Evensen MK, Needham KE et al. (1981) Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure. Circulation 63:96
Erbel R, Meyer J, Lambertz H et al. (1982) Hemodynamic effects of prenalterol in patients with ischemic heart disease and congestive cardiomyopathy. Circulation 66:361
Pouleur H, van Eyll CH, Hanet C et al. (1988) Long-term effects of xamoterol on left ventricular function and late remodeling: a study in patients with anterior myocardial infarction and single-vessel disease. Circulation 77:1081
Baumann G, Busch U, Permanetter B et al. (1986) Occurrence and function of histamine receptors possible significance of H2-receptor stimulation in catecholamine-insensitive myocardial insufficiency. In: Schölmerich P, Holtmeier HJ, Kroneberg HG (eds) Cardiovascular receptors new pharmacologic and clinical aspects. Thieme, Stuttgart, p 169
Baumann G, Busch U, Permanetter B et al. (1987) Mögliche Bedeutung einer kardialen H2-Rezeptorstimulation bei Katecholamin-refraktärem Myokardversagen unterschiedlichster Ätiologie. In: Brisse B, Bender F (eds) Autonome Inervation des Herzens. Steinkopff, Darmstadt, p 183
Baumann G, Ningel K, Permanetter B (1989) Cardiovascular profile of UDCG 115 BS pimobendane and reversibility of catecholamine subsensitivity in severe con gestive heart failure secondary to idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 13:730
Brodde OE, Schuler S, Kretsch R et al. (1986) Regional distribution of ß-adrenoceptors in the human heart: coexistence of functional ß1- and ß2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol 8:1235
Stiles GL, Taylor S, Lefkowitz RJ (1983) Human cardiac ß-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci 33:467
Heitz A, Schwartz J, Velly J (1983) ß-Adrenoceptors of the human myocardium: determination of ß1 and ß2 subtypes by radioligand. Br J Pharmacol 80:711
Golf S, Lovstad R, Hnsson V (1985) ß-Adrenoceptor density and relative number of ß-adrenoceptor subtypes in biopsies from human right atrial, left ventricular and right ventricular myocardium. Cardiovasc Res 19:636
Bristow MR, Ginsburg R, Fowler M et al. (1986) ß1- And ß2-adrenergic receptor subpopulations in normal and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective ß1 receptor down-regulation in heart failure. Circ Res 59:297
Bristow MR, Ginsburg R (1986) ß Receptors are present on myocardial cells in human ventricular myocardium. Am J Cardiol 57:3F
Baumann G, Felix STB, Sackmann I, Klein G (1989) An open study to assess the effects of dopexamine on urinary output and haemodynamics in patients with chronic cardiac failure and to compare these effects with those produced by dobutamine. Eur Heart J (in press)
Baumann G, Gutting M, Pfafferott C et al. (1988) Comparison of acute haemodynamic effects of dopexamine hydrochloride, dobutamine and sodium nitroprusside in chronic heart failure. Eur Heart J 9:503
Alousi AA, Farah AE, Lesher GY et al. (1979) Cardiotonic activity of amrinone -WIN 40680 (5-amino-3,4’-bipyridine-6(lH)-one). Circ Res 45:666
Ross G, Dobestani AI, Patel AL (1981) Effect of amrinone on vascular smooth muscle. Fed Proc 40:659 (abstr)
Sonnenblick EH, Mancini DM, LeJemtel TH (1989) New inotropic drugs for the treatment of heart failure: promises and limitations. Am J Cardiol (in press)
Levine SD, Jacoby M, Satriano JA et al. (1981) The effects of amrinone on transport and cAMP metabolism in toad urinary bladder. J Pharmacol Exp Ther 216:220
Scholz H, Meyer W (1986) Phosphodiesterase inhibiting properties of newer inotropic agents. Circulation [Suppl III] 73:III–108
Rapundalo St, Grupp I, Grupp G et al. (1986) Myocardial actions of rnilrinone: characterization of its mechanism of action. Circulation 73 [Suppl III]:III–134
Colucci WS, Wright RF, Braunwald E (1986) New positive inotropic agents in the treatment of congestive heart failure (pt 2). N Engl J Med 314:349
Feldman MD, Copelas L, Gwathmey JK et al. (1987) Pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75:331
Baumann G, Mercader D, Permanetter B, Busch U, Ningel K, Wirtzfeld A, Blömer H (1985) A new therapeutic approach on congestive heart failure: combined phosphodiesterase inhibition with simultaneous H2-receptor stimulation. In: Ganellin CR, Schwartz JC (eds) Frontiers in histamine research. Pergamon, New York, p 325 (Advances in the biosciences, vol 54)
Baumann G, Buschauer A, Permanetter B et al. (1988) New aspects for the treatment of congestive heart failure. Innere Medizin 15:30
Naccarelli GV, Gray EL, Dougherty AH et al. (1984) Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. Am J Cardiol 54:600
Nasrat A, Tepper D, Hertzberg J et al. (1983) Effects of amrinone on atrioventricular conduction in the intact canine heart. J Clin Pharmacol 23:257
Alousi AA, Farah AE, Lesher GY et al. (1979) Cardiotonic activity of amrinone WIN 40680. Circ Res 45:666
Maskin CS, Forman R, Klein NA et al. (1982) Long-term amrinone therapy in pa tients with severe heart failure. Am J Med 72:113
Weber KT, Andrews V, Janicki JS et al. (1981) Amrinone and exercise performance in patients with chronic heart failure. Am J Cardiol 48:164
Siskind SY, Sonnenblick EH, Forman R et al. (1981) Acute substantial benefits of inotropic therapy with amrinone on exercise hemodynamics and metabolism in severe congestive heart failure. Circulation 64:966
LeJemtel TH, Keung E, Ribner HS et al. (1980) Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure. Am J Cardiol 45:123
Baumann G, Felix STB, Ningel K, Klein G (1989) Piroximone. Vasodilatation versus inotropy: a group comparative study of hemodynamic responses in chronic congestive heart failure with sodium nitroprusside, piroximone (MDL 19205) and dobutamine. Eur Heart J (in press)
Wynne J, Malacoff RF, Benotti JR et al. (1980) Oral amrinone in refractory congestive heart failure. Am J Cardiol 45:1245
Sterling Winthrop Research Institute (1982) Clinical experience with amrinone: overall summary for NDA amendment. Sterling Winthrop Research Institute, Rensselaer NY
Baumann G, Permanetter B, Wirtzfeld A (1984) Possible value of H2-receptor agonists for treatment of catecholamine-insensitive congestive heart failure. Pharmacol Ther 24:177
Scholtysik G, Salzmann R, Berthold R et al. (1985) DPI 20106, a novel cardioactive agent. Combination of cAMP-independent positive inotropic, negative chronotropic action potential prolonging and coronary dilatory properties. Naunyn Schmiedeberg’s Arch Pharmacol 329:316
Rüegg JC (1986) Effects of new inotropic agents on Ca2+ sensitivity of contractile proteins. Circulation 73 [Suppl III]:III–78
Katz AM (1978) A new inotropic drug: its promise and a caution. N Engl J Med 29:1409
Kirk ES, LeJemtel TH, Nelson GR et al. (1976) Mechanisms of beneficial effects of vasodilators and inotropic stimulation in the experimental failing ischemic heart. Am J Med 65:189
LeJemtel TH, Sonnenblick EH (1984) Should the failing heart be stimulated? N Engl J Med 310:1384
Baumann G, Rieß G, Felix STB et al. (1981) Catecholamines and ß-adrenergic receptors in the non-ischemic myocardium after coronary occlusion. In: Delius W, Gerlach E, Grobecker X, Kübier W (eds) Catecholamines and the heart, vol 72. Springer, Berlin Heidelberg New York, p 91
Baumann G, Felix STB, Schrader J et al. (1981) Cardiac contractile and metabolic effects mediated via the myocardial H2-receptor adenylate cyclase system: characterization of two new specific H2-receptor-agonists, impromidine and dimaprit, in the guinea pig and human myocardium. Res Exp Med (Berl) 179:81–98
Baumann G, Felix STB, Rieß G, Loher U, Ludwig L, Blömer H (1982) Effective stimulation of cardiac contractility and myocardial metabolism by impromidine and dimaprit two new H2-agonistic compounds in the surviving, catecholamineinsensitive myocardium after coronary occlusion. J Cardiovasc Pharmacol 4:542–553
Baumann G, Rieß G, Erhardt WD, Felix STB, Blömer H (1980) Reduzierte ß-adrenerge Ansprechbarkeit im nicht ischämischen Myokard nach experimentellem Herzinfarkt. Z Kardiol 69:209
Baumann G, Schrader J, Gerlach E (1981) Inhibitory action of adenosine on histamine and dopamine-stimulated cardiac contractility and adenylate cyclase in guinea pigs. Circ Res 48:259–266
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Baumann, G., Felix, S.B. (1989). Sympathomimetic vs Non-Sympathomimetic Drugs in the Treatment of Heart Failure. In: Reinhart, K., Eyrich, K. (eds) Clinical Aspects of O2 Transport and Tissue Oxygenation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83872-9_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-83872-9_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-51470-1
Online ISBN: 978-3-642-83872-9
eBook Packages: Springer Book Archive